Citations

Clear

367 citation(s) found for "Du, Pan".

Pan‐cancer analysis of prognostic metastatic phenotypes
Wang, Xi , Garrett, Sara M. , Lehrer, Eric J. , Lin, Christine , DeGraff, David J. , Spratt, Daniel E. , Kishan, Amar U. , Park, Henry S. , Yang, Jonathan T. , Zaorsky, Nicholas G , Garrett, Sara M , Spratt, Daniel E , Park, Henry S , Zaorsky, Nicholas G. , Trifiletti, Daniel M. , Showalter, Timothy N. , Chinchilli, Vernon M , Wang, Ming

Mayo Clinic

International Journal of Cancer | July 20, 2021 | Volume: 150 | Issue: 1 | Pages: 132-141

10.1002/ijc.33744 | PMID 34287840 Get It

AbstractAlthough cancer is highly heterogeneous, all metastatic cancer is considered American Joint Committee on Cancer (AJCC) Stage IV disease. The purpose of this project was to redefine staging of metastatic cancer. Internal validation of nationally representative patient data from the National Cancer Database (n = 461 357; 2010‐2013), and external validation using the Surveillance, Epidemiology and End Results database (n = 106 595; 2014‐2015) were assessed using the concordance index for evaluation of survival prediction. A Cox proportional hazards model was used for overall survival by considering identified phenotypes (latent classes) and other confounding variables. Latent class analysis was performed for phenotype identification, where Bayesian information criterion (BIC) and sample‐size‐adjusted BIC were used to select the optimal number of distinct clusters. Kappa coefficients assessed external cluster validation. Latent class analysis identified five metastatic phenotypes with differences in overall survival (P < .0001): (Stage IVA) nearly exclusive bone‐only metastases (n = 59 049, 12.8%; median survival 12.7 months; common in lung, breast and prostate cancers); (IVB) predominant lung metastases (n = 62 491, 13.5%; 11.4 months; common in breast, stomach, kidney, ovary, uterus, thyroid, cervix and soft tissue cancers); (IVC) predominant liver/lung metastases (n = 130 014, 28.2%; 7.0 months; common in colorectum, pancreatic, lung, esophagus and stomach cancers); (IVD) bone/liver/lung metastases predominant over brain (n = 61 004, 13.2%; 5.9 months; common in lung and breast cancers); and (IVE) brain/lung metastases predominant over bone/liver (n = 148 799, 32.3%; 5.7 months; lung cancer and melanoma). Long‐term survivors were identified, particularly in Stages IVA‐B. A pan‐cancer nomogram model to predict survival (STARS: site, tumor, age, race, sex) was created, validated and provides 13% better prognostication than AJCC: 1‐month concordance index of 0.67 (95% confidence interval [CI]: 0.66‐0.67) vs 0.61 (95% CI: 0.60‐0.61). STARS is simple, uses easily accessible variables, better prognosticates survival outcomes and provides a platform to develop novel metastasis‐directed clinical trials.
Abstract 386: A Novel Aquaretic and Glomerular Filtration Rate Enhancing Peptide Without Vascular Vasodilatory Actions in Experimental CHF.
Chen, Horng H. , Pan, Shuchong, Burnett, John C. , Simari, Robert D.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 116 | Issue: suppl_16 | Pages: No page available

10.1161/circ.116.suppl_16.ii_61-b Get It

BACKGROUND: BNP is a cardiac peptide with vasodilatory, natriuretic and diuretic properties. Recent studies have suggested that its vasodilatory hypotensive properties may limit the renal actions of BNP, especially in patients with borderline low blood pressure. We have recently identified an alternatively spliced transcript for BNP (ASBNP) that includes a unique and distinct longer carboxyl-terminus consisting of 34 amino acids. Based upon preliminary studies, we generated a truncated form (ASBNP2.1) that contains the first 16 amino acids of the C-terminal of ASBNP. METHODS: We determined the cardiorenal and humoral actions of intravenous infusion of ASBNP2.1 at 2 pmol/Kg/min, 10 pmol/Kg/min and 100 pmol/Kg /min in 10 dogs with rapid ventricular pacing induced overt CHF (240 bpm for 10 days). * p<0.05 RESULTS: IV infusion of ASBNP 2.1 increased aquaresis (from 0.19±0.04 to 0.32±0.07, 0.46±0.11 and 0.39±0.09 ml/min*) without a significant change in urinary sodium excretion. Importantly, ASBNP 2.1 enhanced glomerular filtration rate (GFR), from 31±4 to 47±8, 69±10 and 56±9 ml/min*. These renal actions were associated with increases in urinary BNP*, ANP* and cGMP* excretion. BNP 2.1 did not have any systemic vasodilatory action resulting in no change in mean arterial blood pressure or cardiac-filling pressures even at the highest dose. There was not change in serum sodium concentration. CONCLUSION: We report for the first time that this novel peptide based upon ASBNP has potent aquaretic and GFR enhancing actions without the vasodilatory hypotensive properties in an experimental model of overt CHF. The lack of vasodilatation but with renal actions also suggest that the C-terminus plays a key role in the vascular actions of this peptide offering new insights into vascular-renal structure function of BNP and related peptides. This renal specific peptide may have potential therapeutic benefit in states of renal dysfunction with volume overload to enhance GFR and water excretion without the detrimental side effect of hypotension.
Abstract 1479: Pan-cancer efficacy of BRAF and/or MEK inhibitors in BRAF V600-mutant multiple non-melanoma cancers: A clinico-genomic study
Adashek, Jacob J. , Menta, Arjun K. , Desai, Aakash , Roszik, Jason , Subbiah, Vivek

Mayo Clinic

Cancer Research | July 1, 2021 | Volume: 81 | Issue: 13_Supplement | Pages: 1479-1479

10.1158/1538-7445.am2021-1479 Get It

Abstract Background: BRAF and MEK inhibitors are currently FDA approved for melanoma, non-small cell lung cancer, and anaplastic thyroid cancer. The lack of clinical benefit with BRAF inhibition in BRAF V600+ colorectal cancer (CRC) has prevented its tissue-agnostic drug development. However, updated results from Vemurafenib-Basket study (Cancer Discov. 2020 May;10(5):657-663 ) and the NCI-match trial ( J Clin Oncol. 2020 Nov 20;38(33):3895-3904) reveal that BRAF pathway inhibition is active in &gt; 20 unique cancer types. Objective: We aimed to describe the characteristics of BRAF V600 and study real-world outcomes using a clinico-genomic analysis using the AACR Genie database and the current medical literature. Methods: We reviewed the AACR GENIE database for the prevalence of BRAF V600 mutations across tumor types. We conducted a literature search (using PubMed from 2012-2019) for case reports of clinical response and outcomes in patients with BRAF V600 mutation-positive non-melanoma cancers who received BRAF inhibitor therapy. Results: Among 96,324 samples, BRAF V600 mutations were seen in 43 different tumor types across 2,963 samples (3.07 %) in the AACR GENIE database. BRAF V600 was most commonly present in thyroid cancer (40.9%), parathyroid cancer (31.8%), melanoma (26.1%), histiocytosis (25.7%), and head and neck NOS (14.3%). Literature review revealed total of 178 cases across 69 tumor types. The most common cases included Erdheim-Chester disease (n = 30, 16.9%), papillary thyroid carcinoma (n=16, 8.9%), anaplastic thyroid carcinoma (n = 13, 7.3%), and hairy cell leukemia (n = 13, 7.3%). Furthermore, dabrafenib (BRAF), dabrafenib/trametinib (BRAF+MEK), trametinib(MEK), vemurafenib (BRAF), vemurafenib/trametinib (BRAF+MEK), vemurafenib/cobimetinib (BRAF+MEK) were used in 34% (n =56), 16% (n = 27), 4% (n = 6), 44% (n = 72), 1% (n = 1), 2% (n =3), respectively. Overall, median PFS was 6.5 months, and median OS was 28.5 months with a median duration of response (DOR) of 8 months. Conclusion: BRAF V600 mutations are prevalent across multiple non-melanoma cancers, lead to oncogene addiction and are clinically actionable in a broad range of non-melanoma cancers. Continued drug development is warranted beyond the current BRAF+/- MEK approved cancers. Citation Format: Jacob J. Adashek, Aakash P. Desai, Arjun K. Menta, Jason Roszik, Vivek Subbiah. Pan-cancer efficacy of BRAF and/or MEK inhibitors in BRAF V600-mutant multiple non-melanoma cancers: A clinico-genomic study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1479.
Circulating tumour DNA reveals genetic traits of patients with intraductal carcinoma of the prostate
Zhao, Jinge , Sun, Guangxi , Dai, Jindong, Chen, Junru , Zhang, Mengni , Ni, Yuchao , Shen, Pengfei , Zhao, Xiaochen , Zhang, Bei , Pan, Xiuyi , Yin, Xiaoxue , Liang, Jiayu, Wang, Zhipeng , Liao, Banghua , Liu, Zhenhua , Armstrong, Cameron M. , Chen, Ni , Zeng, Hao , Wang, Zhipeng , Zeng, Hao , Chen, Junru , Wang, Zhipeng , Zhu, Sha , Zhang, Haoran , Nie, Ling , Zhang, Xingming , Zhu, Xudong , Gao, Allen C , Huang, Haojie

Mayo Clinic

BJU International | June 29, 2021 | Volume: 129 | Issue: 3 | Pages: 345-355

10.1111/bju.15530 | PMID 34185954 Get It

Objectives To investigate the genetic alterations of patients with prostate cancer (PCa) with and without intraductal carcinoma of the prostate (IDC‐P). Patients and Methods We performed targeted sequencing of plasma cell‐free DNA on 161 patients with prostate adenocarcinoma (PAC) with IDC‐P and 84 without IDC‐P. Genomic alterations were compared between these two groups. The association between genetic alterations and patients’ survival outcomes was also explored. Results We identified that 29.8% (48/161) and 21.4% (18/84) of patients with and without IDC‐P harboured genomic alterations in DNA repair pathways, respectively ( P = 0.210). Pathogenic germline DNA repair alterations were frequently detected in IDC‐P carriers compared to IDC‐P non‐carriers (11.8% [19/161] vs 2.4% [two of 84], P = 0.024). Germline BReast CAncer type 2 susceptibility protein ( BRCA2 ) and somatic cyclin‐dependent kinase 12 ( CDK12 ) defects were specifically identified in IDC‐P carriers relative to PAC ( BRCA2 : 8.7% [14/161] vs 0% and CDK12 : 6.8% [11/161] vs 1.2% [one of 84]). Patients with IDC‐P had a distinct androgen receptor (AR) pathway alteration, characterised by an enrichment of nuclear receptor corepressor 2 ( NCOR2 ) mutations compared with patients with pure PAC (21.1% [34/161] vs 6.0% [five of 84], P = 0.004). Increased AR alterations were detected in patients harbouring tumours with an IDC‐P proportion of ≥10% vs those with an IDC‐P proportion of <10% (6.4% [five of 78] vs 18.1% [15/83], P = 0.045). For IDC‐P carriers, tumour protein p53 ( TP53 ) mutation was associated with shorter castration‐resistant‐free survival (median 10.9 vs 28.9 months, P = 0.026), and BRCA2 alteration was related to rapid prostate‐specific antigen progression for those receiving abiraterone treatment (median 9.1 vs 11.9 months, P = 0.036). Conclusion Our findings provide genomic evidence explaining the aggressive phenotype of tumours with IDC‐P, highlighting the potential therapeutic strategies for this patient population.
Insights of fibroblast growth factor receptor 3 aberrations in pan-cancer and their roles in potential clinical treatment
Li, Juanni , Huang, Jinzhou , Xu, Zhijie , Xu, Zhijie , Hu, Kuan , Zhou, Lei , Yan, Yuanliang

Mayo Clinic

Aging | June 23, 2021 | Volume: 13 | Issue: 12 | Pages: 16541-16566

10.18632/aging.203175 | PMID 34160364 Get It

Abstract WP425: Effects of Angiotensin II on Expression and Processing of Amyloid Precursor Protein in Human Cerebral Microvascular Endothelial Cells
Sun, Ruohan , He, Tongrong , Pan, Yujun , Katušić, Zvonimir S.

Mayo Clinic

Stroke | June 21, 2021 | Volume: 48 | Issue: suppl_1 | Pages: No page available

10.1161/str.48.suppl_1.wp425 Get It

Background and Purpose: Molecular mechanisms underlying increased risk of Alzheimer’s disease in hypertensive patients are poorly defined. Conflicting results have been reported regarding the effects of angiotensin II (Ang II) on expression of amyloid precursor protein (APP) and enzymes responsible for proteolytic cleavage of APP in the brain. However, no previous studies have directly assessed the effects of Ang II on metabolisms of APP in human endothelial cells. Current study was designed to determine the effects of Ang II on the expression and processing of APP in cultured human brain microvascular endothelial cells (hBMECs). Methods: Human BMECs were treated with increasing concentrations of Ang II (0.1nM to 100nM; incubation time = 24h). The protein expression of APP, α-secretase [a disintegrin and metalloprotease 10, (ADAM10), ADAM9, and ADAM17], β-secretase (β-site APP-cleaving enzyme, BACE1), NADPH oxidase subunits and endothelial nitric oxide synthase (eNOS) were measured by western blot. Production and release of amyloid β-peptides (Aβ) from endothelium were detected by ELISA. Results: In hBMECs, Ang II had no effect on the expression of APP (n=7-9, P>0.05) and α-secretase (ADAM10, n=7-9, P>0.05; ADAM9, n=4-7, P>0.05; ADAM17, n=4-7, P>0.05). Treatment with Ang II at 1nM concentration induced significant increase in BACE1 expression (n=13, P<0.05), however, we did not observe significant changes in production of Aβ40 (n=11, P>0.05) or Aβ42 (n=11, undetectable). The higher concentration of Ang II (100nM) increased expression of NOX4 (n=6, P<0.05). In addition, Ang II (1nM and 10nM) significantly up-regulated eNOS protein levels (n=8-10, P<0.05). Conclusion: Our findings suggest that in hBMECs: a) Ang II does not affect expression of APP and α-secretase-mediated cleavage of APP, and b) Ang II increases expression of BACE1 but does not elevate production and release of Aβ peptides. We also confirm previously reported ability of Ang II to increase expression of NOX4 and eNOS. We speculate that under pathological conditions, increased expression of BACE1 induced by Ang II may predispose cerebrovascular endothelium to elevated amyloidogenic processing of APP.
The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers
Amin, Mahul B. , Epstein, Jonathan I. , Hansel, Donna E. , Paner, Gladell P. , True, Larry, Bayder, Dilek, Bivalacqua, Trinity J. , Brimo, Fadi , Cheng, Liang , Cheville, John C. , Dalbagni, Guido , Falzarano, Sara M. , Gordetsky, Jennifer , Gupta, Sounak , Hes, Ondřej , Kaushal, Seema , Kunju, Lakshmi P., McKenney, Jesse K. , Netto, George J. , Osunkoya, Adeboye O. , Pan, Chin , Pivovarcikova, Kristina, Raspollini, Maria Rosaria , Reis, Henning , Trpkov, Kiril , Weyerer, Veronika , Zhou, Ming , Reuter, Victor, Cheng, Liang , Cheng, Liang , Gordetsky, Jennifer B , Trpkov, Kiril , Compérat, Éva , Al-Ahmadie, Hikmat A , Guo, Charles Chuanhai , Iyer, Gopa , Magi‐Galluzzi, Cristina , Matoso, Andres , Pan, Chin Chen, Rosenberg, Jonathan E , Rouprêt, Morgan , Shah, Rajal B. , Shariat, Shahrokh F.

Mayo Clinic

Advances in Anatomic Pathology | June 15, 2021 | Volume: 28 | Issue: 4 | Pages: 196-208

10.1097/pap.0000000000000309 | PMID 34128484 Get It

The Genitourinary Pathology Society (GUPS) undertook a critical review of the recent advances in bladder cancer focusing on important topics of high interest for the practicing surgical pathologist and urologist. This review represents the second of 2 manuscripts ensuing from this effort. Herein, we address the effective reporting of bladder cancer, focusing particularly on newly published data since the last 2016 World Health Organization (WHO) classification. In addition, this review focuses on the importance of reporting bladder cancer with divergent differentiation and variant (subtypes of urothelial carcinoma) histologies and the potential impact on patient care. We provide new recommendations for reporting pT1 staging in diagnostic pathology. Furthermore, we explore molecular evolution and classification, emphasizing aspects that impact the understanding of important concepts relevant to reporting and management of patients.
The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia
Amin, Mahul B. , Epstein, Jonathan I. , True, Lawrence D. , Hansel, Donna E. , Paner, Gladell P. , Baydar, Dilek Ertoy , Bivalacqua, Trinity J. , Brimo, Fadi , Cheng, Liang , Cheville, John C. , Dalbagni, Guido , Falzarano, Sara M. , Gordetsky, Jennifer , Gupta, Sounak , Hes, O., Kaushal, Seema , Kunju, Lakshmi P., Netto, George J. , Osunkoya, Adeboye O. , Pan, Chin , Pivovarcikova, Kristina, Raspollini, Maria Rosaria , Reis, Henning , Trpkov, Kiril , Weyerer, Veronika , Zhou, Ming , McKenney, Jesse K. , Reuter, Victor E. , Cheng, Liang , Cheng, Liang , Gordetsky, Jennifer B , Trpkov, Kiril , Compérat, Éva , Al-Ahmadie, Hikmat A , Guo, Charles Chuanhai , Iyer, Gopa , Magi‐Galluzzi, Cristina , Matoso, Andres , Pan, Chin Chen, Rosenberg, Jonathan E , Rouprêt, Morgan , Shah, Rajal B. , Shariat, Shahrokh F.

Mayo Clinic

Advances in Anatomic Pathology | June 15, 2021 | Volume: 28 | Issue: 4 | Pages: 179-195

10.1097/pap.0000000000000308 | PMID 34128483 Get It

The Genitourinary Pathology Society (GUPS) undertook a critical review of the recent advances in bladder neoplasia with a focus on issues relevant to the practicing surgical pathologist for the understanding and effective reporting of bladder cancer, emphasizing particularly on the newly accumulated evidence post-2016 World Health Organization (WHO) classification. The work is presented in 2 manuscripts. Here, in the first, we revisit the nomenclature and classification system used for grading flat and papillary urothelial lesions centering on clinical relevance, and on dilemmas related to application in routine reporting. As patients of noninvasive bladder cancer frequently undergo cystoscopy and biopsy in their typically prolonged clinical course and for surveillance of disease, we discuss morphologies presented in these scenarios which may not have readily applicable diagnostic terms in the WHO classification. The topic of inverted patterns in urothelial neoplasia, particularly when prominent or exclusive, and beyond inverted papilloma has not been addressed formally in the WHO classification. Herein we provide a through review and suggest guidelines for when and how to report such lesions. In promulgating these GUPS recommendations, we aim to provide clarity on the clinical application of these not so uncommon diagnostically challenging situations encountered in routine practice, while also importantly advocating consistent terminology which would inform future work.
Integrative Pan-cancer Analysis of MEK1 Aberrations and the Potential Clinical Implications
Li, Juanni , Huang, Jinzhou , Cai, Yuan, Zhou, Zhiyang , Bi, Peng , Cai, Yuan, Xu, Zhijie , Yan, Yuanliang

Mayo Clinic

No container title available | April 9, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-392196/v1 Get It

Abstract Background: Alterations of mitogen-activated protein kinase kinase 1 (MEK1) are commonly associated with tumorigenesis, and MEK1 is thought to be a suitable targeted therapy for various cancers. However, abnormal MEK1 alterations and their relevant clinical implications are unknown. Our research comprehensively analyzed the MEK1 alteration spectrum and provided novel insight for targeted therapies. Methods: There were 7694 samples covering 32 types of cancer from The Cancer Genome Atlas (TCGA) database. They were used to conduct an integrative analysis of MEK1 expression, alterations, functional impacts and clinical significance. Results: There was a dramatic difference in the alteration frequency and distribution and clinical implications in 32 types of cancer from the TCGA. Skin cutaneous melanoma (SKCM) has the most alterations and has therapeutic targets located in the protein kinase domain, and the growing expression of SKCM is positively related to patient prognosis. MEK1 expression in lung adenocarcinoma (LUAD), kidney renal papillary cell carcinoma (KIRP), esophageal carcinoma (ESCA) and liver hepatocellular carcinoma (LIHC) is decreased, which is associated with better prognosis, while MEK1 expression in thymoma (THYM), stomach adenocarcinoma (STAD), kidney renal clear cell carcinoma (KIRC), testicular germ cell tumors (TGCTs) and head and neck squamous cell carcinoma (HNSC) is increased, which is associated with better prognosis. Mesothelioma (MESO) has the second highest alterations but has no therapy targets. Conclusion: This study provided a great and detailed interpretation of MEK1 expression, alterations and clinical implications in 32 types of cancer and reminded us to fill the gap in MEK1 research from a new perspective. Keywords: MEK1, gene mutation, gene alteration, outcome, pan-cancer
Plasma Cell–Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate Cancer
Kwan, Edmond M. , Dai, Chao , Fettke, Heidi , Hauser, Christine , Docanto, Maria, Bukczynska, Patricia , Ng, Nicole , Foroughi, Siavash , Graham, Lisa-Jane K., Tan, Winston , Wang, Xiaohong , Zhao, Zhixin , Zhou, Kemin , Yu, Jianjun , Du, Pan , Jia, Shidong , Azad, Arun , Kohli, Manish , Azad, Arun A , Mahon, Kate Lynette , Zheng, Tiantian , Horvath, Lisa G. , Kohli, Manish

Mayo Clinic

JCO Precision Oncology | April 6, 2021 | Volume: No volume available | Issue: 5 | Pages: 622-637

10.1200/po.20.00424 | PMID 34250422 Get It

PURPOSETumor tissue from metastatic castration-resistant prostate cancer (mCRPC) harbors frequent copy number variations (CNVs) in the PTEN-PI3K-AKT pathway. However, identifying CNVs in plasma cell–free DNA (cfDNA) has proven to be challenging. With emerging data supporting Akt inhibition in PTEN-deficient mCRPC, we profiled PTEN-PI3K-AKT pathway aberrations in patients with mCRPC using a novel cfDNA assay optimized for CNV detection.METHODSA next-generation sequencing–based cfDNA assay was used to profile 231 patients with mCRPC from two independent cohorts (Australian, n = 78; United States, n = 153). PTEN-PI3K-AKT pathway genomic aberrations were correlated with clinical outcomes, including progression-free survival and overall survival (OS).RESULTSPTEN loss and PIK3CA gain were detected in 37% (85 of 231) and 17% (39 of 231) of patients, respectively. Poorer outcomes were observed in patients with PTEN-PI3K-AKT pathway aberrations, including those with dual PTEN loss and PIK3CA gain (hazard ratio 2.3, 95% CI 1.2 to 4.4). Cumulative CNV burden in the PTEN-PI3K-AKT and androgen receptor (AR) pathways was associated with significantly worse clinical outcomes (0 v 1 v ≥ 2 CNVs in Australian cohort: median OS 33.5 v 17.2 v 9.7 months, P < .001; 0 v 1 v ≥ 2 CNVs in US cohort: median OS 35.5 v 14.3 v 9.2 months, P < .001). Notably, 21% (31 of 146) of PTEN-neutral patients harbored alternative PTEN-PI3K-AKT pathway aberrations.CONCLUSIONPTEN-PI3K-AKT pathway CNVs were readily detected using our cfDNA assay, with the prevalence of PTEN loss comparable with tissue-based studies. Additional PTEN-PI3K-AKT pathway aberrations were found in one fifth of PTEN-neutral cases. Concurrent CNVs in the PTEN-PI3K-AKT and AR pathways portended poor survival, and identifying this high-risk patient subset for dual AR/Akt inhibition may optimize precision treatment with Akt inhibitors in mCRPC.